دورية أكاديمية
Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims.
| العنوان: | Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims. |
|---|---|
| المؤلفون: | Zhu C; Biogen, Cambridge, MA 02142, USA., Zaidman C; Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA., Youn B; Biogen, Cambridge, MA 02142, USA., Paradis AD; Biogen, Cambridge, MA 02142, USA., Raynaud S; Biogen, Cambridge, MA 02142, USA., Neville BA; Biogen, Cambridge, MA 02142, USA., Johnson NB; Biogen, Cambridge, MA 02142, USA. |
| المصدر: | Journal of comparative effectiveness research [J Comp Eff Res] 2024 Jul 04, pp. e230187. Date of Electronic Publication: 2024 Jul 04. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Becaris Publishing Country of Publication: England NLM ID: 101577308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6313 (Electronic) Linking ISSN: 20426305 NLM ISO Abbreviation: J Comp Eff Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Royston, UK : Becaris Publishing Original Publication: London : Future Medicine |
| مستخلص: | Aim: Nusinersen, administered by intrathecal injection at a dose of 12 mg, is indicated across all ages for the treatment of spinal muscular atrophy (SMA). Evidence on real-world healthcare resource use (HRU) and costs among patients taking nusinersen remains limited. This study aimed to evaluate real-world HRU and costs associated with nusinersen use through US claims databases. Patients & methods: Using the Merative™ MarketScan ® Research Databases, patients with SMA receiving nusinersen were identified from commercial (January 2017 to June 2020) and Medicaid claims (January 2017 to December 2019). Those likely to have complete information on the date of nusinersen initiation and continuous enrollment 12 months pre- and post-index (first record of nusinersen treatment) were retained. Number and costs (US$ 2020) of inpatient admissions and emergency department (ED) visits, unrelated to nusinersen administration, were evaluated for 12 months pre- and post-nusinersen initiation and stratified by age: pediatric (<18 years) and adult (≥18 years). Results: Overall, 103 individuals treated with nusinersen were retained: 59 were pediatric (mean age [range]: 9 [1-17] years), and 44 were adults (30 [18-63] years). Inpatient admissions decreased by 41% for pediatrics and 67% for adults in the 12 months post-treatment versus the 12 months pre-treatment. Average inpatient admission costs per patient for the pediatric cohort decreased by 63% ($22,903 vs $8466) and by 79% ($13,997 vs $2899) for the adult cohort when comparing the 12 months pre-index with the 12 months post-index period. Total ED visits and ED visit costs decreased by 8% and 35%, respectively, for the overall cohort over the 12-month period pre- and post-index. Conclusion: Using US claims databases, nusinersen treatment in pediatric and adult patients was associated with reductions in HRU and costs over a 12-month period post-treatment initiation relative to the pre-treatment period. |
| References: | J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1166-1174. (PMID: 32917822) Gene Ther. 2017 Sep;24(9):529-533. (PMID: 28644430) Lancet Neurol. 2020 Apr;19(4):317-325. (PMID: 32199097) Neurology. 2014 Aug 26;83(9):810-7. (PMID: 25080519) Neuromuscul Disord. 2018 Mar;28(3):197-207. (PMID: 29305137) J Pediatr. 2020 Apr;219:223-228.e4. (PMID: 32035635) Front Neurol. 2021 Apr 16;12:650532. (PMID: 33935949) J Med Econ. 2020 Jan;23(1):70-79. (PMID: 31322019) Muscle Nerve. 2023 Aug;68(2):157-170. (PMID: 37409780) Ther Adv Neurol Disord. 2018 Feb 05;11:1756285618754501. (PMID: 29434670) Drugs. 2017 Mar;77(4):473-479. (PMID: 28229309) Adv Ther. 2023 Mar;40(3):1129-1140. (PMID: 36645543) J Neuromuscul Dis. 2021;8(4):569-578. (PMID: 33843692) N Engl J Med. 2018 Feb 15;378(7):625-635. (PMID: 29443664) Paediatr Respir Rev. 2021 Sep;39:54-60. (PMID: 33129670) Pediatr Pulmonol. 2022 Jun;57(6):1505-1512. (PMID: 35307979) J Mark Access Health Policy. 2020 Nov 8;8(1):1843277. (PMID: 33224449) Neuromuscul Disord. 2019 Nov;29(11):842-856. (PMID: 31704158) Neurol Clin Pract. 2021 Jun;11(3):e317-e327. (PMID: 34476123) Lancet. 2017 Dec 17;388(10063):3017-3026. (PMID: 27939059) Front Neurol. 2021 May 20;12:650535. (PMID: 34093395) N Engl J Med. 2017 Nov 2;377(18):1723-1732. (PMID: 29091570) Orphanet J Rare Dis. 2021 Oct 13;16(1):430. (PMID: 34645478) Nat Rev Dis Primers. 2022 Aug 4;8(1):52. (PMID: 35927425) J Health Econ Outcomes Res. 2019 Dec 2;6(3):185-195. (PMID: 37362080) J Med Econ. 2016 Aug;19(8):822-6. (PMID: 27264163) Neurology. 2019 May 21;92(21):e2492-e2506. (PMID: 31019106) Neurology. 2016 Mar 8;86(10):890-7. (PMID: 26865511) Pediatr Neurol. 2019 Mar;92:3-5. (PMID: 30591237) |
| فهرسة مساهمة: | Keywords: commercial and Medicaid claims; healthcare resource utilization; medical cost offsets; nusinersen; patient-level claims; spinal muscular atrophy |
| تواريخ الأحداث: | Date Created: 20240704 Latest Revision: 20240707 |
| رمز التحديث: | 20240707 |
| مُعرف محوري في PubMed: | PMC11225157 |
| DOI: | 10.57264/cer-2023-0187 |
| PMID: | 38963060 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2042-6313 |
|---|---|
| DOI: | 10.57264/cer-2023-0187 |